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Prospective Relation of Circulating Adipokines to Incident Metabolic
Syndrome: The Framingham Heart Study
Justin P. Zachariah, MD, MPH; Rene Quiroz, MD, MPH; Kerrie P. Nelson, MSc, PhD; Zhaoyang Teng, PhD; John F. Keaney, Jr, MD;
Lisa M. Sullivan, PhD; Ramachandran S. Vasan, MD
Background-—Adipokines are elaborated by adipose tissue and are associated with glycemic, lipid, and vascular traits. We
hypothesized that in a cross-sectional analysis circulating adipokines are altered among subsets of obesity stratiﬁed by presence
versus absence of metabolic syndrome (MetS) and prospectively predict the incidence of MetS.
Methods and Results-—Participants in the community-based Framingham Third Generation Cohort who attended examination
cycle 1 were included in the study (2002–2005; N=3777, mean age, 40 years; 59% women). Circulating adiponectin, leptin, leptin
receptor, fetuin-A, fatty acid–binding protein 4, and retinol binding protein 4 were assayed and related to incident MetS in follow-up
(mean 6 years). The adipokines were compared among individuals with excess body weight (body mass index ≥25 kg/m2) and
prevalent MetS, excess body weight without MetS (metabolically healthy obese), and normal-weight with MetS (metabolically
obese, normal-weight) with normal-weight participants without MetS as a referent. Metabolically healthy obese individuals
(n=1467) had higher circulating levels of fetuin-A and fatty acid–binding protein 4 but lower levels of leptin, leptin receptor, and
adiponectin (P<0.001 for all). The adipokine panel was associated with incident MetS (263 new-onset cases; P=0.002). Higher
circulating concentrations of retinol-binding protein 4 and fetuin-A were associated with incidence of MetS (odds ratio per 1-SD
increment log marker, 1.21; 95% CI, 1.03–1.41 [P=0.02] and 1.17; 95% CI, 1.01–1.34 [P=0.03], respectively).
Conclusions-—In our community-based sample of young to middle-aged adults, metabolically healthy obese individuals
demonstrated an adverse adipokine proﬁle. Higher circulating levels of retinol-binding protein 4 and fetuin-A marked future
cardiometabolic risk. ( J Am Heart Assoc. 2017;6:e004974. DOI: 10.1161/JAHA.116.004974.)
Key Words: adipokine • epidemiology • metabolic syndrome • obesity • risk factor
M etabolic syndrome (MetS) is associated with anincreased risk of diabetes mellitus (DM) and cardiovas-
cular disease (CVD), likely attributable to its constituent
constellation of risk factors.1,2 In addition, there is signiﬁcant
variation in cardiometabolic risk among individuals with similar
bodymass index (BMI). While some persons with excess weight
may have profound metabolic derangements, nearly 40% of
obese individuals have a normal metabolic proﬁle (so-called
metabolically healthy obese [MHO]).3 Conversely, some nor-
mal-weight persons may have substantial metabolic derange-
ments (termed metabolically obese, normal weight [MONW]).
Since BMI alone cannot consistently predict cardiometabolic
risk, researchers have focused on variations in adipose tissue
endocrine function to understand the pathogenesis of car-
diometabolic risk in obese individuals.4,5 Adipokines are
biologically active compounds elaborated by adipose tissue,
with examples including leptin, its counter-regulatory circulat-
ing receptor (LEP-R), adiponectin, fetuin-A, fatty acid–binding
protein 4 (FABP4), and retinol-binding protein 4 (RBP4).6
Investigators have reported that some adipokines individually
predict cardiometabolic risk, but, to our knowledge, the
prospective association of a panel of adipokines for MetS in
both MHO and MONW groups has not been previously
evaluated.6 We hypothesized that in a cross-sectional analysis
both MHO and MONW individuals have an altered circulating
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adipokine proﬁle compared with a referent group with normal
BMI (<25 kg/m2) and without MetS. We also postulated that
in a prospective analysis, an adipokine proﬁle characterized
by higher circulating levels of fetuin-A, FABP4, RBP4, and LEP-
R but lower concentrations of adiponectin and leptin will be
prospectively associated with a greater incidence of MetS.
We tested these hypotheses using a multimarker adipokine
panel in a community-based sample of young to middle-aged
adults.
Methods
Study Procedures
The design and the selection criteria of the Third Generation
Cohort of the Framingham Heart Study have been detailed
elsewhere.7 The institutional review board of Boston Univer-
sity approved the study protocol, and all study participants
provided written informed consent. At each Framingham
Heart Study examination, attendees underwent a routine
medical history with a standardized physical examination
including anthropometry and blood pressure (BP) measure-
ment. After the participant rested in a seated position for
10 minutes, a physician measured the participant’s BP using
a standardized protocol with mercury column sphygmo-
manometer and an appropriately sized cuff. The average of
2 readings constituted the examination BP. Self-reported use
of cigarettes within the year preceding the baseline exami-
nation was deﬁned as current smoking.
Attendees underwent laboratory assessment of other risk
factors in a fasting state. Phlebotomy was performed after
participants rested for 10 minutes in the supine position.
Specimens were stored at 80°C without freeze-thaw cycles
until assay. Fasting levels of plasma high-density lipoprotein
cholesterol, triglycerides, insulin, and glucose were measured
using standardized assays. Plasma levels of fetuin-A and FABP4
were measured using sandwich ELISA (BioVendor Reasearch
and Diagnostic Products). Plasma levels of leptin, LEP-R, RBP4,
and adiponectin were measured using ELISA (R&D Systems).
The average interassay coefﬁcients of variation for the
biomarkers were as follows: leptin 4.97%, LEP-R 4.01%, FABP4
2.38%, RBP4 2.18%, fetuin-A 2.52%, and adiponectin 2.23%.
Study Samples
For the present study, participants who attended the ﬁrst
examination cycle (2002–2005) were eligible. Of 4095
participants who attended the ﬁrst baseline examination,
221 individuals were excluded for having missing adipokine
data, 53 for missing covariates, 44 for prevalent CVD (deﬁned
as coronary heart disease, congestive heart failure, intermit-
tent claudication, or cerebrovascular disease), and one for
missing serum creatinine. The remaining 3777 participants
(sample 1) were included in the cross-sectional adipokine
analyses (Figure 1).
For the prospective analyses, we used a 2-step analysis
where longitudinal associations were identiﬁed between
adipokines and incident MetS at the follow-up examination
in participants without MetS at the baseline examination.
Adipokines identiﬁed at this step were examined for longitu-
dinal associations with individual change in components of
MetS measured between the baseline and follow-up exami-
nations. Of examination cycle 1 attendees, 2669 participants
Figure 1. Flow diagram of respective sample inclusion/
exclusion criteria. CVD indicates cardiovascular disease; MetS,
metabolic syndrome.
Clinical Perspective
What is New?
• Since the association between obesity and MetS traits is
variable, we explored the association between circulating
adipokines and future incidence of MetS.
• We observed that higher levels of RBP4 and fetuin-A were
associated with future incidence of MetS.
What are the Clinical Implications?
• With future investigation, circulating adipokines may serve
to identify persons at high risk of MetS.
• Future studies may also explore the role of adipokines in the
pathophysiology of MetS and the association between MetS
and atherosclerotic events.
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subsequently attended examination cycle 2 (2008–2011), a
mean of 6 years after the baseline examination (sample 2),
and were examined for associations with the individual MetS
traits. Of sample 2, a total of 461 participants were excluded
for prevalent MetS at the baseline examination, prevalent
CVD, prevalent DM (use of antiglycemic agents or fasting
plasma glucose ≥100 mg/dL), serum creatinine >2.0 mg/dL,
missing adipokine data, or missing covariates, leaving 2208
participants (sample 3) eligible for analyses relating adipokine
concentrations to the incidence of MetS.
Outcome Deﬁnition
Using the National Cholesterol Education Program Adult
Treatment Panel III guidelines, MetS was deﬁned as the
presence of 3 or more of the following: elevated BP
(≥130 mm Hg systolic, ≥85 mm Hg diastolic) or treatment
for high BP; hypertriglyceridemia (≥150 mg/dL) or treatment
with lipid-lowering treatment; low high-density lipoprotein
cholesterol (<40 mg/dL in men, <50 mg/dL in women);
hyperglycemia (fasting glucose ≥100 mg/dL) or treatment
with oral hypoglycemic agents or insulin; and increased waist
circumference (≥102 cm for men, ≥88 cm for women).1,2
Statistical Analyses
Adipokine concentrations were standardized within sex
(mean=0, SD=1) to account for sex differences in their
distributions. Pairwise Pearson correlation coefﬁcients were
calculated to assess the relations among the adipokines. The
homeostasis model assessment insulin resistance index
(HOMA-IR) was calculated using the formula: fasting
insulin9fasting glucose/22.5.8
Cross-sectional analyses
Participants were grouped according to BMI <25 kg/m2
versus ≥25 kg/m2 (normal weight and overweight, respec-
tively). Participants were divided into 4 groups: (1) absence of
MetS and BMI <25 kg/m2; (2) presence of MetS and BMI
<25 kg/m2 (MONW); (3) absence of MetS and BMI ≥25 kg/
m2 (MHO); and (4) presence of MetS and BMI ≥25 kg/m2 (at
risk for overweight). Using the absence of MetS and BMI
<25 kg/m2 as the referent group, we compared the mean
levels of adipokines among the 4 groups.
Longitudinal analyses: multimarker panel and incidence
of MetS
We used a conservative 2-step multimarker strategy to relate
the adipokines (modeled as sex-standardized continuous vari-
ables) to the incidence ofMetS in participants in sample 3. First,
we used multivariable logistic regression to relate the entire
panel of adipokines to incident MetS. We adjusted for age, sex,
and baseline MetS component levels, which included waist
circumference.We estimated a chi-square test–derived global P
value using a likelihood ratio test examining the difference
between the 2 log-likelihood models of clinical covariates
alone versus clinical covariates plus all adipokines as a panel. If
the panel global P value was <0.05, we then used backward
elimination (threshold of P<0.05 for retention in the model) to
select a ﬁnal parsimonious set of “informative” adipokines.
In secondary analyses, to explore whether the association
of adipokines with incident MetS was confounded by insulin
resistance, HOMA-IR was added as an additional covariate to
the multivariable model. A receiver operator curve comparing
the models with versus without HOMA-IR in the prediction of
MetS at follow-up examination was constructed. The MetS
prediction C statistic (area under the receiver operating
characteristic curve) for participants missing HOMA-IR data
was not signiﬁcantly different than those with HOMA-IR (0.82
versus 0.83), therefore participants with missing HOMA-IR
data were included to maximize statistical power. We also
used age and sex interaction terms to examine effect
modiﬁcation on the biomarker-MetS relationship. To ascertain
nonlinearity in the adipokine-MetS association, we con-
structed restricted cubic splines with 3 knots corresponding
to quartile cut points. We assessed the conjoint inﬂuence of
informative adipokines on incident MetS by cross-classifying
participants according to sex-standardized median values and
determining whether individuals with values above the median
(“high”) for ≥1 adipokines had a greater risk of developing
MetS compared with those with the concentrations of the
informative adipokines at or below the median (“low”). These
models were adjusted for age, sex, baseline BMI (except for
models with waist circumference as the dependent variable),
and baseline level of the individual risk factor analyzed.
Longitudinal analyses: adipokines and longitudinal
changes in MetS components
Finally, the association between the baseline informative
adipokine levels (modeled together as continuous variables)
with longitudinal changes in the levels of individual MetS
components separately were examined in the 2669 partici-
pants from sample 2, excluding participants using BP- or lipid-
lowering treatment at baseline for BP and triglyceride
analyses, respectively. In sex-pooled multivariable logistic
regression models, the change in each MetS component was
the dependent variable (separate analysis for each compo-
nent) and informative sex-standardized, natural logarithmically
transformed adipokines as the independent variables. For
waist circumference, change was sex-standardized. For
systolic BP, diastolic BP, plasma glucose, and log-triglycer-
ides, we used censored normal regression to account for
DOI: 10.1161/JAHA.116.004974 Journal of the American Heart Association 3
Adipokines and Metabolic Syndrome Prediction Zachariah et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on A
ugust 30, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Table 1. Baseline Characteristics of Study Sample 1
Clinical Features
Sample 1 (n=3777) Sample 2 (n=2669) Sample 3 (n=2208)
Men (n=1747) Women (n=2030) Men (n=1202) Women (n=1467) Men (n=907) Women (n=1301)
Age, y 40.1837 40.08.8 40.28.5 40.18.7 39.38.6 39.58.6
Systolic BP, mm Hg 12013 11314 12012 11314 11811 11112
Diastolic BP, mm Hg 789 739 789 729 769 719
BP ≥130/85 or
treatment, %
36 19 18.3 9.8 9.5 5.9
Hypertension, % 12.0 7.8 19.0 10.0 9.5 6.1
Treatment for
hypertension, %
9.4 7.0 8.0 5.3 3.2 3.4
BMI, kg/m² 27.84.6 26.06.1 27.74.4 25.55.5 26.53.7 24.64.7
BMI ≥30 kg/m², % 25.0 20.1 23.8 17.9 13.6 12.8
Weight, kg 88.115.8 70.016.7 87.615.0 68.715.2 83.913.0 66.413.1
Waist circumference,
cm
98.112.6 88.415.7 97.612.0 87.114.3 94.210.4 84.812.5
Elevated waist
circumference, %*
32.5 41.4 31.0 39.0 17.4 31.7
Plasma total
cholesterol, mg/dL
19337 18534 19436 18432 19136 18332
Plasma triglycerides,
mg/dL
134108 9763 12992 9252 10462 8235
Elevated
triglycerides, %†
29.4 13.0 27.3 10.7 12.7 4.3
Plasma HDL-C,
mg/dL
4712 6116 4712 6216 5011 6415
Low HDL-C, %‡ 28.7 23.9 27.5 21.8 14.6 15.5
Change in
weight, kg§
NA NA 37 37 36 37
Smoking, % 15.9 14.3 15.6 13.4 15.8 12.2
Fasting plasma
glucose, mg/dL
9817 9218 968 908 947 897
Impaired fasting
glucose, %k
3.32 1.92 0.3 0.1 0.1 0.1
HOMA-IR 1.41.2 1.10.9 1.30.9 1.00.7 1.00.5 0.90.5
Biomarkers, median (quartile 1–3)
CRP mg/L 0.90 (0.4–2.1) 1.21 (0.5–3.4) 0.88 (0.4–2.0) 1.1 (0.4–3.2) 0.7 (0.3–1.6) 1.0 (0.4–2.7)
Leptin, ng/mL 6.0 (2.3–7.4) 18.0 (6.5–23.5) 4.1 (2.4–7.1) 11.6 (6.2–22.1) 3.4 (2.0–5.5) 10.2 (5.7–19.3)
Leptin receptor,
ng/mL
18.9 (12.7–23.5) 19.9 (13.0–25.0) 17.4 (11.9–22.9) 18.3 (12.3–24.7) 18.5 (12.3–23.6) 18.9 (12.6–25.3)
Fetuin-A, ng/mL 442.5 (325.1–524.1) 469.1 (337.3–570.4) 409.3 (321.2–521.4) 438.6 (329.1–571.2) 408.3 (323.9–516.5) 434.4 (325.7–571.4)
RBP4, ng/mL 43.9 (39.6–49.6) 38.2 (30.6–44.7) 42.8 (36.9–49.4) 36.6 (30.6–44.6) 42.2 (36.4–48.1) 36.1 (30.3–43.6)
FABP4, ng/mL 16.6 (10.9–19.9) 21.7 (13.2–25.9) 14.7 (10.6–19.3) 17.5 (12.8–24.6) 13.2 (9.9–17.6) 16.6 (12.3–22.2)
Adiponectin,
lg/mL
6.1 (3.3–7.9) 10.9 (6.5–14.6) 5.3 (3.4–8.0) 10.3 (6.9–14.7) 5.9 (3.9–8.5) 10.7 (7.6–15.1)
Values for clinical features are meansSD or percentages and for adipokines are median and 25%–75% interquartile range. BMI indicates body mass index; BP, blood pressure; CRP,
C-reactive protein; FABP4, fatty acid–binding protein 4; HOMA-IR, homeostasis model assessment insulin resistance index; NA, not available; RBP4, retinol-binding protein 4.
*Waist circumference ≥40.2 inches (102 cm) in men, ≥34.6 inches (88 cm) in women.
†
Triglycerides ≥150 mg/dL or treatment.
‡High-density lipoprotein cholesterol (HDL-C) <40 mg/dL in men, <50 mg/dL in women.
§Change in weight from examination 1 to examination 2.
kGlucose ≥100 mg/dL.
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initiating treatment of high BP, DM, or dyslipidemia by the
follow-up examination.9 For all analyses, a 2-sided P value of
<0.05 was considered statistically signiﬁcant. All analyses
were performed with SAS (version 9.2, SAS Institute) and R
(version 2.12).
Results
Baseline Adipokines and Clinical Characteristics
Baseline clinical characteristics of samples 1, 2, and 3 are
shown in Table 1. Mean values of circulating leptin, adiponec-
tin, and FABP4 were higher in women than in men. Mean values
of fetuin-A and RBP4 according to sex and age younger than 40
or 40 years and older among BMI and MetS groups are seen in
Figure 2. Compared with nonattendees, sample 2 participants
generally had lower BP, rates of obesity, triglyceride levels,
proportion of smoking, and blood sugar (Table 2). Modest
pairwise correlations were noted among the adipokines
(r=0.30 to +0.55; Table 3). Stronger correlations were
demonstrated for leptin andHOMA-IR or FABP4 (r=0.55 for both).
Cross-Sectional Findings
Baseline characteristics according to presence/absence of
MetS and by BMI group are summarized in Table 4.
Participants with normal weight represented roughly 41% of
sample 1, 19% had MetS, 39% were MHO, and 1% were
MONW. In age- and sex-adjusted models, leptin, fetuin-A,
RBP4, and FABP4 were higher in the MHO group (compared
with the referent group; P value for all <0.01). Leptin-R and
adiponectin were signiﬁcantly lower in the MHO group than in
the referent group (P value for both P<0.001).
Relation of the Adipokine Panel to Incident MetS
A total of 263 participants (113 women) in sample 2
developed new-onset MetS on follow-up. The panel of
biomarkers was associated with incidence of MetS (global
test, P=0.004). On multivariable logistic regression with
backward elimination of adipokines and adjusted for baseline
MetS component levels, higher plasma RBP4 (adjusted OR per
1-SD increment, 1.21; 95% CI, 1.03–1.41 [P=0.02]) and
fetuin-A (1.17; 95% CI, 1.01–1.34 [P=0.03]) were signiﬁcantly
associated with development of new-onset MetS. Table 5
shows quartile-based analyses where circulating RBP4 was
associated with a 17% increased risk of MetS per quartile
increment, whereas fetuin-A increased risk of future MetS by
16% per quartile increment. Restricted cubic splines demon-
strating the association between fetuin-A or RBP4 and future
development of MetS is seen in Figure 3. Analysis of incident
MetS risk among binary categories of RBP4 and fetuin-A
Figure 2. Least square mean and standard error of plasma fetuin and retinol-binding protein 4 (RBP4). The x axis represents different subgroups
(presence/absence of metabolic syndrome [MetS] and normal/overweight). The y axis represents least square mean for fetuin and RBP4.
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dichotomized at the median shows that the individuals with
levels of both RBP4 and fetuin-A above the median experi-
enced a higher risk compared with the group with both
adipokines at or below the median (Table 5).
Circulating RBP4 and Fetuin-A and Longitudinal
Tracking of MetS Components
In multivariable-adjusted logistic regression models, circulat-
ing RBP4 and fetuin-A were associated with longitudinal
changes in systolic BP and borderline statistically signiﬁcant
associations with higher fasting glucose (Table 6). In addition,
blood RBP4 was signiﬁcantly associated with an increase in
diastolic BP (P=0.007).
Discussion
We evaluated circulating concentrations of a panel of adipoki-
nes in younger adults with normal weight, MONW individuals,
and MHO individuals cross-sectionally, and the incidence of
MetS prospectively. Overall, MHO participants exhibited an
abnormal adipokine proﬁle and MONW participants also had
trends toward abnormal adipokine proﬁle. Circulating RBP4
and fetuin-A were associated with incident MetS and long-
itudinal increase in systolic BP, while RBP4 was associated
with signiﬁcantly higher diastolic BP and a trend toward higher
fasting glucose. Overall, our data extend to young to middle-
aged adults in previous work associating certain adipokines to
one or more metabolic traits in middle to older adults.10,11
Table 2. Baseline Characteristics of Participants in Study Sample 2 vs Nonattendees
Clinical Features
Men Attending
Examination 2 (n=1202)
Men Not Attending
Examination 2 (n=710) P Value
Women Attending
Examination 2 (n=1467)
Women Not Attending
Examination 2 (n=716) P Value
Age, y 40.2 (8.5) 40.5 (9.4) 0.481 40.1 (8.7) 39.9 (9.1) 0.751
Systolic BP, mm Hg 120.0 (12.1) 122.2 (13.3) 0.001 112.8 (14.0) 114.1 (15.1) 0.050
Diastolic BP, mm Hg 78.0 (9.2) 79.0 (9.4) 0.025 72.3 (9.2) 73.4 (9.2) 0.009
Hypertension, % 19.0 27.3 <0.0001 10.0 16.3 <0.0001
Treatment for hypertension, % 8.0 14.1 <0.0001 5.3 11.2 <0.0001
BMI, kg/m² 27.7 (4.4) 28.4 (5.2) 0.002 25.5 (5.5) 27.2 (7.1) <0.0001
BMI ≥30 kg/m², % 23.8 29.5 0.005 17.9 26.9 <0.0001
Weight, kg 87.6 (15.0) 89.4 (17.4) 0.017 68.7 (15.2) 72.9 (19.4) <0.0001
Waist circumference, cm 97.6 (12.0) 99.5 (13.7) 0.002 87.1 (14.3) 91.5 (18.0) <0.0001
Total cholesterol, mg/dL 193.7 (36.2) 191.9 (38.9) 0.335 184.3 (32.2) 187.0 (34.5) 0.092
Triglycerides, mg/dL 128.7 (91.9) 149.2 (135.5) 0.001 91.8 (50.6) 109.5 (80.3) <0.0001
HDL-C, mg/dL 46.9 (11.9) 46.5 (13.4) 0.508 61.9 (15.8) 59.0 (16.3) <0.0001
Current smoker, % 15.6 23.4 <0.0001 13.4 21.9 <0.0001
Fasting plasma glucose, mg/dL 95.9 (7.6) 103.6 (27.6) <0.0001 89.8 (7.5) 96.9 (29.3) <0.0001
Values for clinical features are meansSD or percentages. BMI indicates body mass index; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model
assessment insulin resistance index.
Table 3. Adipokine Intercorrelations
Leptin Leptin Receptor Fetuin-A RBP4 FABP4 Adiponectin CRP HOMA-IR
Leptin 1.00 0.21* 0.07* 0.04 0.55* 0.18* 0.29* 0.55*
Leptin receptor 1.00 0.04* 0.11* 0.12* 0.17* 0.09* 0.17*
Fetuin-A 1.00 0.06* 0.04* 0.02 0.05* 0.10*
RBP4 1.00 0.07* 0.003 0.04* 0.05*
FABP4 1.00 0.22* 0.21* 0.40*
Adiponectin 1.00 0.12* 0.30*
CRP 1.00 0.24*
HOMA-IR 1.00
CRP indicates C-reactive protein; FABP4, fatty acid–binding protein 4; HOMA-IR, homeostasis model assessment insulin resistance index; RBP4, retinol-binding protein 4.
*Values are Pearson correlation coefﬁcients (n=2416) for sex-standardized, age-adjusted adipokines in natural units.
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Cross-Sectional Data on Adipokine
Concentrations in Subsets of Obesity
It is estimated that 28% of the US population older than
20 years is MHO, while the prevalence of MONW is 8.1%.3
The prevalence of metabolically healthy obesity was 39% in
our current study, similar to US, Swedish, and prior
Framingham estimates, while our rate of MONW was roughly
1%.12,13 The CVD risk of these respective categories is
somewhat controversial. Some studies identify an elevated
risk of CVD events in obese persons without cardiometabolic
risk factors, while other studies have found no elevated
risk.14–16 These conﬂicting results may be explained by
different follow-up periods and event rates between studies.
On the other hand, there is evidence that persons with
cardiometabolic risk factors in the context of normal body
weight have an elevated risk for both experiencing a CVD
event and developing DM.15
Table 4. Baseline Examination Characteristics Cross-Classiﬁed by Weight vs MetS Category
Clinical Features
Absence of MetS Presence of MetS
BMI <25
(n=1560)
MHO Participants
(n=1467)
MONW
Participants (n=36) BMI ≥25 (n=714)
Age, y 38.4 39.8 43.0 43.7
Systolic BP, mm Hg 111 117 125 128
Diastolic BP, mm Hg 71 76 81 83
BP ≥130/85 mm Hg or treatment, % 13.0 20.3 77.8 74.1
Hypertension, % 13.0 20.3 77.8 74.1
Treatment for hypertension, % 3.5 3.5 22.2 17.1
BMI, kg/m² 22.2 29.0 23.5 32.8
BMI ≥30 kg/m², % 0 27.5 0 61.8
Weight, kg 63 85 68 98
Waist circumference, cm 80 98 90 110
Increased waist circumference, %* 5.4 48.0 33.3 85.2
Total cholesterol, mg/dL 180 192 202 202
Triglycerides, mg/dL 82 103 252 202
High triglycerides, %† 11.1 20.0 66.7 72.3
HDL-C, mg/dL 54 54 45 42
Low HDL-C, %‡ 14.0 17.5 77.8 66.7
Smoking, % 14.8 13.1 22.2 19.2
Fasting plasma glucose, mg/dL 90 64 102 108
Impaired fasting glucose, %§ 0.51 0.89 5.56 10.36
Biomarkers, mean (95% CIs)
HOMA-IR 0.86 1.16 1.29 2.21
Leptin, ng/mL 4.1 (3.7–4.5) 16.4 (15.7–17.1) 7.8 (5.7–9.9) 22.8 (21.6–24.0)
Leptin receptor, ng/mL 22.1 (21.5–22.6) 18.4 (18.0–18.8) 20.4 (18.4–22.4) 16.5 (16.0–17.1)
Fetuin-A, ng/mL 439.4 (430.5–488.2) 458.8 (449.4–468.2) 455.6 (399.8–511.4) 490.2 (476.7–503.6)
RBP4, ng/mL 39.7 (39.1–40.2) 40.6 (40.1–41.1) 50.1 (45.1–55.1) 43.6 (42.7–44.5)
FABP4, ng/mL 13.5 (13.1–13.9) 21.3 (20.8–21.8) 21.7 (18.0–25.4) 28.2 (27.2–29.3)
Adiponectin, lg/mL 10.4 (10.1–10.7) 8.2 (8.0–8.5) 6.1 (4.9–7.4) 5.8 (5.5–6.1)
Values for clinical features are means or percentages, biomarkers are age and sex adjusted means with 95% CI. BMI indicate body mass index; BP, blood pressure; FABP4, fatty acid–
binding protein 4; HOMA-IR, homeostasis model assessment insulin resistance index; MetS, metabolic syndrome; MHO, metabolically healthy obese; MONW, metabolically obese, normal-
weight; RBP4, retinol-binding protein 4.
*Waist circumference ≥40.2 inches (102 cm) in men, ≥34.6 inches (88 cm) in women.
†Triglycerides ≥150 mg/dL or treatment.
‡High-density lipoprotein cholesterol (HDL-C) <40 mg/dL in men, <50 mg/dL in women.
§Glucose ≥100 mg/dL.
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Metabolically abnormal proﬁles appear to be more fre-
quent with advancing age (10% among persons aged 20 to
34 years; 56% among persons aged 80 years or older),
suggesting that metabolically healthy obesity may be an early
phenotype that can worsen to greater cardiometabolic risk
over time.3 In a Finnish population, 20% of men and 24% of
women were MONW, possibly reﬂecting ethnic differences in
the proportion of metabolic derangement compared with our
Table 5. Logistic Regression Analysis Examining Biomarkers in Quartiles and in Combinations to Incidence of MetS
No. of Cases/
No. of People at Risk*
Unadjusted Incidence
Rates % (95% CI)
Multivariable Adjusted†
OR (95% CI) P Value
RBP4
Quartile 1 47/591 8.0 (5.7–10.2) Referent
Quartile 2 64/568 11.3 (8.5–14.0) 1.39 (0.90–2.16) 0.14
Quartile 3 70/552 12.7 (9.7–15.7) 1.25 (0.81–1.94) 0.32
Quartile 4 82/497 16.5 (12.9–20.1) 1.75 (1.12–2.78) 0.02
Trend   1.17 (1.01–1.35) 0.03
Fetuin-A
Quartile 1 50/559 8.9 (6.5–11.4) Referent
Quartile 2 68/557 12.2 (9.3–15.1) 1.28 (0.84–1.96) 0.25
Quartile 3 69/550 12.5 (9.6–15.5) 1.47 (0.97–2.24) 0.07
Quartile 4 76/542 14.0 (10.9–17.2) 1.59 (1.05–2.42) 0.03
Trend   1.16 (1.02–1.33) 0.03
Marker combination
Both ≤ median 42/579 7.3 (5.1–9.4) Referent
Either RBP4 or fetuin-A below median 134/1050 12.8 (10.6–14.9) 1.48 (1.01–2.22) 0.05
Both above median 87/579 15.0 (11.9–18.2) 1.70 (1.10–2.65) 0.02
OR indicates odds ratio for log-transformed adipokine; RBP4, retinol-binding protein 4.
*Excludes participants with metabolic syndrome (MetS) at baseline, and uses sex-standardized biomarkers (which explains why the number at risk differs for each quartile).
†Multivariable models are adjusted for age, sex, baseline body mass index, sex-standardized waist circumference, systolic and diastolic blood pressure, high-density lipoprotein cholesterol,
glucose, and log of triglycerides.
Figure 3. Association between fetuin-A or retinol-binding protein 4 (RBP4) and incident metabolic syndrome (MetS) using restricted cubic
splines with 3 knots. Knots represent the ﬁrst, second (median), and third quartile values, with the reference as the ﬁrst (or lower) quartile value.
The x axis represents the range of values for each respective adipokine and the y axis represents the log (odds ratio [OR]) for a 1-unit increase in
the sex-standardized adipokine. CL indicates 95% conﬁdence limit.
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cohort.17 Beyond epidemiological differences, our data sug-
gest key biological distinctions between MHO and MONW
groups. The leptin pathway and adiponectin appeared to track
with participants with obesity in that the MHO pattern was
associated with higher leptin and lower LEP-R in participants
with normal weight. The MONW participants appeared to be
intermediate between metabolically healthy obesity and
normal weight in leptin and LEP-R, while overweight
participants with MetS had the highest levels of leptin and
lowest LEP-R and adiponectin. Therefore, the monotonically
higher free leptin that can be inferred by the gap between
measured leptin and LEP-R levels among categories of normal
weight, MONW, metabolically healthy obesity, and overweight
with MetS may reﬂect the dominant role played by weight in
driving leptin pathway levels. In contrast, adiponectin levels
were highest in normal-weight individuals, lower in MHO
individuals, and lowest in MONW and overweight individuals
with MetS, suggesting it may be a strong driver of
cardiometabolic risk in these individuals. Comparable levels
of fetuin and FABP4 were shown in MHO and MONW persons,
which were higher than those in normal-weight persons but
lower than those in overweight individuals with MetS,
suggesting a codependent pattern where cardiometabolic
risk or excess weight each drive abnormalities in these
adipokines. Finally, RBP4 showed a pattern of elevation more
consistent with cardiometabolic risk rather than with weight
per se, since circulating concentrations in metabolically
healthy obesity and normal weight were largely similar.
RBP4 and Risk of MetS
We observed that higher plasma RBP4 concentrations were not
only associated with cross-sectional presence of MetS but also
prospectively associated with incident MetS. Higher circulating
RBP4 concentrations were speciﬁcally associated with higher
systolic and diastolic BPs and with borderline higher fasting
glucose level on follow-up. These ﬁndings are consistent with
previous reports linking RBP4 to dysglycemia, vascular prop-
erties, and hypertension.18–20 RBP4 may be an intriguing
predictor of cardiometabolic risk, especially given that serum
levels of RBP4 have appeared to be independent of obesity and
previously noted to be elevated in nonobese, insulin-resistant
patients.20,21 RBP4 is a transport protein highly expressed in
liver and adipose tissue.22,23 Overexpression of RBP4 results in
insulin resistance, while, conversely, knockout of the protein
translates into enhanced insulin sensitivity.20,24 Serum RBP4
levels have previously been inversely correlated with insulin
sensitivity in nondiabetic patients and are increased in patients
with impaired glucose tolerance, type 2 DM, fatty liver, cerebral
infarction, and components of MetS, particularly triglyc-
erides.20,25–27 RBP4 has been shown to be a relevant marker
for the prediction of prevalent MetS in cross-sectional,
community-based samples of elderly patients, although less
is known about its effects on younger patient populations or in
prospective studies.25,28 Our data clarify and extend previous
observations to younger adult populations.
Fetuin-A and Risk of MetS
In our sample, plasma fetuin-A levels were positively associ-
ated with MetS cross-sectionally and with greater risk of
incident MetS longitudinally, speciﬁcally with elevation in
systolic BP and trends toward higher fasting glucose on
follow-up, consistent with previous reports. Fetuin-A inhibits
insulin receptor signaling in liver and muscle via tyrosine
kinase activity, thereby promoting hepatic and skeletal
muscle insulin resistance.29–31 Fetuin-A knockout mice have
been shown to have enhanced insulin sensitivity, resistance to
weight gain, and lower triglyceride levels.30 Higher serum
fetuin-A levels have been associated with risk of type 2 DM,
Table 6. Logistic Regression Analysis Examining the Incidence of Individual Risk Factors From Baseline Examination to Follow-Up
Examination According to Biomarkers (Modeled Together)
D MetS Component No.
Incidence
Proportion, %
RBP4 Fetuin-A
Multivariable Adjusted*
OR (95% CI) P Value
Multivariable Adjusted*
OR (95% CI) P Value
Waist circumference 2208 916/2208 (41.5%) 1.05 (0.93–1.18) 0.42 1.04 (0.92–1.18) 0.5
Fasting glucose 2207 369/2208 (16.7%) 1.13 (0.99–1.28) 0.06 1.03 (0.90–1.17) 0.07
Systolic BP 2206 411/2206 (18.6%) 1.22 (1.06–1.39) 0.004 1.14 (1.00–1.30) 0.04
Diastolic BP 2206 394/2206 (17.8%) 1.19 (1.04–1.13) 0.007 1.08 (0.95–1.22) 0.26
Triglycerides 2206 441/2206 (20.0%) 1.08 (0.96–1.23) 0.19 0.99 (0.88–1.11) 0.80
HDL-C 2208 238/2206 (10.8%) 1.05 (0.89–1.22) 0.58 1.09 (0.94–1.26) 0.26
BP indicates blood pressure; HDL-C, high-density lipoprotein cholesterol; RBP4, retinol-binding protein 4.
*Multivariable-adjusted beta for change (D) in components of metabolic syndrome (MetS) are adjusted for age, sex, baseline body mass index (except waist circumference model), and
baseline level of the individual component, and values are per SD increment of log biomarkers.
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myocardial infarction and ischemic stroke, MetS, and speciﬁc
components of MetS.10,32–35
Study Strengths and Limitations
The strengths of our investigation include the moderately sized
community-based sample, the routine assessment of several
circulating adipokines in a younger adult sample, a design that
included cross-sectional and longitudinal components, the
adjustment for several standard clinical covariates in multi-
variable analyses, and the assessment of the conjoint associ-
ations of several adipokines. These adipokines may provide
novel insights into the pathophysiological progression to MetS.
The limitations of our investigation include the “single
occasion” measurement of adipokines that may not ade-
quately capture their biologic activity or variability over time.
The sample size of the MONW group was small (n=36), limiting
our statistical power to assess associations for this group. Our
sample consists of mostly white participants, therefore
generalizability to other ethnicities is limited. The differences
between included participants and nonattendees may also
limit generalizability of our ﬁndings to persons with higher CVD
risk. Lastly, the follow-up period in the current study was
6 years, and we may have underestimated the long-term
metabolic risks associated with adipokine proﬁles. This, in
part, may explain why both circulating RBP4 and fetuin-A
concentrations demonstrated borderline statistically signiﬁ-
cant associations with fasting blood glucose concentrations.
Conclusions
In our community-based sample of young to middle-aged
adults, distinctive cross-sectional patterns of adipokine eleva-
tions were observed in normal-weight, overweight with MetS,
MHO, and MONW participants. Longitudinally, circulating
fetuin-A and RBP4 concentrations were associated prospec-
tively with the incidence of MetS and of speciﬁc MetS
components, even after adjustment for baseline MetS compo-
nent levels. Additional studies of other age groups and
multiethnic samples are warranted to conﬁrm the role of these
adipokines in the incipient MetS and cardiometabolic conse-
quences. Future work may identify adipokines as screening
tools to identify persons at high risk for MetS and CVD events.
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